跳至主要内容
临床试验/NCT03942926
NCT03942926Unknown2 期

The Efficacy and Safety of Sirolimus for Plastic Bronchitis:a Pilot Study

Peking Union Medical College Hospital1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2019年5月6日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
入组人数
10
试验地点
1
主要终点
changes of coughing score

研究概览

简要总结

There is no confirmed drug therapy for plastic bronchitis. The study wish to test the effectiveness and safety of sirolimus (rapamycin) in patients with lymphatic plastic bronchitis.

详细描述

Plastic bronchitis is a rare respiratory disorder characterized by formation of gelatinous or rigid cast of bronchial tree. Confirmed drug therapy for plastic bronchitis is lacking. Recently, part of plastic bronchitis has been found to have dysfunction of lymphatic circulation in the lung. Pulmonary lymphatic perfusion syndrome (PLPS) is regarded as a major mechanism of lymphatic plastic bronchitis. Sirolimus (rapamycin) has not been studied in plastic bronchitis, however, it has been shown effective in several lymphatic disorders, such as lymphangioleiomyomatosis, generalized lymphatic anomaly (GLA) including lymphangiomatosis, etc. We wish to test the effectiveness of sirolimus in lymphatic plastic bronchitis.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
13 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • plastic bronchitis
  • pulmonary lymphatic perfusion syndrome demonstrated on 68Ga-NEB positron emission tomography (PET)

排除标准

  • Pregnancy and breastfeeding
  • Severe cardiovascular, hepatic and renal dysfunction
  • allergy to sirolimus or 68Ga-NEB

研究组 & 干预措施

Sirolimus

Experimental

Patients in sirolimus group will receive sirolimus for 6 months.

干预措施: Sirolimus (Drug)

结局指标

主要结局

changes of coughing score

时间窗: 6 months

measured by coughing VAS score (0-10) at baseline, 3 months and the end of study

changes of pulmonary lymphatic perfusion distribution

时间窗: 6 months

quantitatively measured with 68Ga-NEB positron emission tomography (PET) at baseline and the end of study

次要结局

  • changes of breathlessness score(6 months)
  • Number of participants with treatment-related adverse events as assessed by CTCAE v4.0(6 months)
  • change of health-related quality of life(6 months)
  • changes of pulmonary function (FEV1, FVC)(6 months)
  • changes of six minutes walking distance(6 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验